Cell>Point enters deal for commercialization of imaging agents

03/14/2013 | Business Wire

Cell>Point said it has secured a licensing deal with South Korean firm Hanmi Pharmaceutical. The agreement involves the development and commercialization of Cell>Point's cancer and cardiology imaging agent, to be developed through its ethylenedicysteine-glucosamine technology. The partnership will initially produce technetium-99m-labeled EC-G for SPECT and SPECT/CT uses. The collaboration will cover gallium-68-labeled EC-G for PET/CT imaging later on.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC